Moderna in the news
mRNA-based drug development
Tamtam found 20 recent articles about Moderna.
- mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
Moderna's mRNA-1283 vaccine is more effective than Pfizer's BNT162b2 in preventing medically attended COVID-19 and hospitalizations in older veterans.
- Moderna falls 2.17% in Friday's session
Moderna's shares decreased by 2.17% to $195.00 on November 20, 2026, resulting in a market value of $77.37 billion.
- Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
Moderna's stock has risen due to its personalized cancer vaccine and diversified pipeline, while BioNTech's stock has fallen despite its oncology pipeline and substantial cash reserves, with both companies pivoting from their initial COVID-19 vaccine success.
- Moderna stock: Intismeran filing target keeps oncology in focus
Moderna aims to file for US approval of its personalized cancer therapy, intismeran, by late 2026, following positive Phase III melanoma results and ongoing trials in other cancers.
- Moderna (NASDAQ:MRNA) Stock Price Up 4.9% - Here's Why
Moderna's stock price rose by 4.9% on Friday, driven by positive vaccine trial results but tempered by future cost concerns and mixed analyst ratings, despite strong Q3 earnings.
- What A Cancer Vaccine Stumble Means For Moderna Stock
Moderna's stock price is highly dependent on its experimental cancer vaccine with Merck, despite its existing revenue coming primarily from COVID vaccines and having substantial cash reserves.
- Moderna (MRNA) Stock Price Prediction: Analyst targets diverge as price slips back under key moving averages
Moderna's stock price is trading below key moving averages, with mixed analyst price targets and technical indicators suggesting a cautious short-term outlook.
- Moderna (NASDAQ:MRNA) Faces Pressure Despite Strong Results
Moderna experienced stock pressure despite strong quarterly results and ongoing advancements in mRNA-based vaccines and cancer research.
- Bireme Capital Sold Moderna (MRNA) Following Record Rally
Bireme Capital sold its Moderna shares in Q3 2026 after the stock's significant rally, following the success of Moderna's intismeran autogene in melanoma trials.
- Moderna Just Dropped 17% in a Week as 2027 Cash Costs Head to $4 Billion. Time to Sell, or Load Up?
Moderna's stock fell 17% due to higher projected cash costs for cancer drug development, exceeding future revenue estimates, raising financial sustainability concerns.
- 21yo law student dies after Covid vaccine
A coronial inquest is investigating the death of a 21-year-old law student from heart failure after a Moderna Covid vaccine booster, with medical experts debating the preventability and cause, while Moderna disputes the primary role of vaccine-induced myocarditis.
- Moderna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,215 Shares
Moderna's President sold over $8.2 million in company stock as the company's shares experienced a slight decline, despite positive recent earnings.
- Moderna supplies COVID-19 vaccine for high-risk infants and children in South Korea
Moderna Korea delivered 1,000 doses of its COVID-19 vaccine for high-risk infants and children in South Korea through collaboration with government agencies.
- New Vaccine, Old False-Claim Playbook
Anti-vaccine activists are misrepresenting data from a government database to falsely claim Moderna's new mRNA flu vaccine is dangerous.
- Insider Selling: Moderna (NASDAQ:MRNA) President Sells 39,160 Shares of Company Stock
Moderna's President sold over $8.6 million in company stock, while the company's shares experienced a decline despite recent positive earnings and clinical trial news.
- Moderna at Jefferies Global Healthcare Conference: oncology push builds
Moderna presented a strong oncology strategy at the Jefferies Global Healthcare Conference, focusing on its personalized cancer vaccine intismeran with positive Phase III melanoma data and ongoing trials for other cancers.
- Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
Moderna is pursuing National Immunisation Program listings for two mRNA flu vaccines, which will be reviewed by the PBAC in March 2027.
- Moderna 600% YTD rally catches cold: What's next amid stock's downtrend?
Moderna shares have dropped about 9.38% in the last week, though they remain up over 600% year-to-date.
- Moderna falls 4.84% in Wednesday's session
Moderna's shares fell 4.84% to 196.79 USD on November 18, 2026, valuing the company at 78.08 billion USD.
- Jefferies Adjusts Price Target on Moderna to $215 From $230
Jefferies has reduced its price target for Moderna from $230 to $215.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Moderna?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies